Browsing by Author "Agboola Abdulmajeed Opeyemi"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Addressing the emerging threat of Oropouche virus: implications and public health responses for healthcare systems
    (Tropical Diseases, Travel Medicine and Vaccines, 2025-01-02) Olalekan John Okesanya; Blessing Olawumi Amisu; Olaniyi Abideen Adigun; Mohamed Mustaf Ahmed; Agboola Abdulmajeed Opeyemi; Tolga Kab; Gilbert Eshun; Bonaventure Michael Ukoaka; Tolutope Adebimpe Oso; Jerico Bautista Ogaya; Don Eliseo Lucero-Prisno III
    Oropouche fever is an increasingly significant health concern in tropical and subtropical areas of South and Central America, and is primarily spread by midge vectors. The Oropouche virus (OROV) was first identified in 1955 and has been responsible for numerous outbreaks, particularly in urban environments. Despite its prevalence, the disease is often under-reported, making it difficult to fully understand its impact. OROV typically causes febrile illness characterized by symptoms such as headaches, muscle pain, and, occasionally, neurological issues such as meningitis. The ability of the virus to thrive in both forested and urban areas has raised concerns regarding its potential spread to new regions, particularly in the context of climate change. This paper delves into the epidemiology, clinical features, and transmission patterns of OROV, shedding light on the difficulties in diagnosing and managing the disease. The absence of specific treatments and vaccines highlights the urgent need for continued research and development of targeted public health strategies. Advancements in molecular diagnostics and vector control strategies can mitigate Oropouche fever’s impact. However, a comprehensive public health approach involving increased surveillance, public education, and cross-border collaboration is needed.
  • Thumbnail Image
    Item
    Bridging the gap to malaria vaccination in Africa: Challenges and opportunities
    (Elsevier Ltd, 2024-01-23) Okesanya Olalekan John; Atewologun Faith; Lucero-Prisno Don Eliseo; Adigun Olaniyi Abideen; Oso Adebimpe Tolutope; Manirambona Emery; Olabode Olaleke Noah; Eshun Gilbert; Okon Ime Inibehe; Agboola Abdulmajeed Opeyemi
    The current state of malaria is devastating owing to the continual dominance of P. falciparum in the African region. Despite progress, the burden remains high, with the African continent contributing significantly to global malaria deaths. The introduction of malaria vaccines, such as RTS,S/AS01 and R21/Matrix-M™, brings hope to the continent, but challenges persist in achieving widespread coverage. Financial constraints, fragmented supply chains, logistical challenges, and vaccine hesitancy are key obstacles. The complex interplay of social, cultural, biological, political, and educational factors further complicates the fight against malaria. To bridge the vaccination gap, a multifaceted approach involving healthcare facilities, governments, non-profit organisations, and global agencies is expedient. It emphasises the importance of community engagement, collaboration with cultural and religious leaders, and leveraging mass media for awareness campaigns tailored to diverse African cultures. Specific recommendations include improving healthcare infrastructure, enhancing access to qualified healthcare providers, creating effective transportation management systems, and implementing comprehensive inventory management policies. Governments are urged to prioritise multistakeholder collaboration, strengthen technical working groups, expedite bureaucratic processes, and invest in multidisciplinary research to identify and address obstacles to malaria vaccination. It calls for cooperative efforts, better data utilisation, improved diagnostics, and comprehensive interventions to reduce the prevalence of malaria and improve public health in Africa. By emphasising the significance of education, knowledge, targeted awareness campaigns, and strategic communication in the malaria vaccine rollout, we can bridge the gaps in malaria vaccination in Africa.
  • Thumbnail Image
    Item
    Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence
    (Sage Journal, 2025-04-15) Rehab Emad Ashmawy; Olalekan John Okesanya; Bonaventure Michael Ukoaka; Faithful Miebaka Daniel; Sonsochukwu Godfrey Ezedigwe; Agboola Abdulmajeed Opeyemi; Mohamed Mustaf Ahmed; Jerico Bautista Ogaya; Blessing Olawunmi Amisu; Olaniyi Abideen Adigun; Olanegan Gloria Oluwakemi; Ayaat Mohamed Hamza; Marina Ramzy Mourid; Don Eliseo Lucero-Prisno, III
    Background Alzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment. Lecanemab has shown safety and efficacy in clinical trials. Objective This review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD. Methods A systematic search was conducted using the Scopus database and ClinicalTrials.gov. Studies from 2014 to 2024 on lecanemab's safety, efficacy, and clinical outcomes for AD were included. Data extraction involved two independent reviewers, with synthesis using qualitative methodology. Results Findings from 13 studies and 13 ongoing clinical trials were reported, showing that lecanemab substantially reduces amyloid plaque load in the brains of AD patients. The therapeutic regimens vary across reported studies and trials, ranging from 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, and 10 mg/kg intravenously biweekly. The Clarity AD phase 3 trial, the AHEAD study, and the DIAN-TU-001 trials have reported positive study outcomes with robust efficacy and safety outcomes with minimal side effects. Completed and ongoing trials report on the onset of amyloid-related imaging abnormalities (ARIA) and the continuation of care status following the onset of ARIA in these patients. The common infusion-related reactions were observed in 26.4% of the lecanemab group compared to 7% in the placebo group. Conclusions The management of AD has evolved over the years with the introduction of novel therapeutic agents like lecanemab. While its safety profile is generally favorable, careful monitoring is essential.